Table 1.

Summary of facility neasurements, before and after drug treatments (mean ± SEM, μl·min^-1·mmHg^-1, n = 6)

Group※	C0	C1	∆C	∆C%	P value
			(C1-C0)	∆C/C0×100%
GPBS	0.25±0.01	0.24±0.03	-0.01±0.02	-5.22±6.75	0.600
Brimonidine	0.25±0.02	0.33±0.04	0.07±0.02	26.65±6.32	0.010*
Latanoprost	0.24±0.03	0.37±0.04	0.12±0.02	54.2±11.5	0.001*
Levobunolol	0.24±0.02	0.25±0.02	0.01±0.01	4.07±4.45	0.390
Brinzolamide	0.22±0.01	0.23±0.02	0.01±0.02	1.23±6.79	0.770
Pilocarpine	0.24±0.02	0.25±0.01	0.01±0.01	2.32±6.06	0.380

^※5.5 mM GPBS and GPBS with corresponding concentration eye drops (4.9×10³ nM Brimonidine, 41.1 nM Latanoprost, 3.4×10³ nM Levobunolol, 3.0×10³ nM Brinzolamide and 8.3×10³ nM Pilocarpine¹).

For 4.9×10³ nM Brimonidine and 41.1 nM Latanoprost showed statistical differences between C₀ and C₁, their concentration was reduced 3 times, while other drugs concentration was improved 10 times to confirm its effectiveness further. Pre-operation (C₀), Post-operation (C₁); P < 0.05.